Benzoylpaeoniflorin

Name: Benzoylpaeoniflorin
Brand: MedChemExpress
SKU: HY-N0852
Rating: 4.5 (1 reviews)

Cat. No.: HY-N0852 Purity: 98.47%: Data Sheet
COA

SDS
Handling Instructions
FAQs
Technical Support

Benzoylpaeoniflorin is an orally active monoterpene glycoside compound. Benzoylpaeoniflorin exerts anti-inflammatory, anti-allergic, psoriasis-improving and sepsis-improving effects by inhibiting signaling pathways such as TNF/NF-κB and MAPK, as well as regulating immune homeostasis. Benzoylpaeoniflorin can be used in research related to immune, allergic and inflammatory diseases.

For research use only. We do not sell to patients.

Benzoylpaeoniflorin Chemical Structure

CAS No. : 38642-49-8

Size	Stock	Quantity
Solid + Solvent (Highly Recommended)
10 mM * 1 mL in DMSO ready for reconstitution	In-stock	Estimated Time of Arrival: December 31
Solution
10 mM * 1 mL in DMSO	In-stock	Estimated Time of Arrival: December 31
Solid
5 mg	In-stock	Estimated Time of Arrival: December 31
10 mg	In-stock	Estimated Time of Arrival: December 31
25 mg	In-stock	Estimated Time of Arrival: December 31
50 mg	In-stock	Estimated Time of Arrival: December 31
100 mg	In-stock	Estimated Time of Arrival: December 31
200 mg	Get quote
500 mg	Get quote

or Bulk Inquiry

* Please select Quantity before adding items.

This product is a controlled substance and not for sale in your territory.

Customer Review

Based on 1 publication(s) in Google Scholar

Other Forms of Benzoylpaeoniflorin:

Benzoylpaeoniflorin (Standard) Get quote

Featured Recommendations

•Related Screening Libraries:

•Related Small Molecules:

•Related Proteins:

View All p38 MAPK Isoform Specific Products:

View All Isoforms

p38 MAPK Akt1 p38α p38β MAPK13 p38δ p38γ

View All NF-κB Isoform Specific Products:

View All Isoforms

NF-κB NF-κB1/p50 RelA/p65 RelB c-Rel

View All Interleukin Related Isoform Specific Products:

View All Isoforms

IL-1 IL-2 IL-3 IL-4 IL-5 IL-6 IL-8 IL-10 IL-12 IL-13 IL-15 IL-17 IL-23 IL-7 IL-33 IL-22 IL-18

View All JNK Isoform Specific Products:

View All Isoforms

JNK1 JNK2 JNK3 JNK

View All CXCR Isoform Specific Products:

View All Isoforms

CXCR CXCR1 CXCR2 CXCR3 CXCR4 CXCR7 CXCR6

Biological Activity
Purity & Documentation
References
Customer Review

Description

IC₅₀ & Target^[1]

IL-1β

IL-6

In Vitro

Benzoylpaeoniflorin (0-800 μM; 24-72 h) shows no cytotoxicity against human HaCaT keratinocytes at concentrations up to 200 μM and exposure durations up to 72 h, while higher concentrations induce dose- and time-dependent cytotoxicity^[1].
Benzoylpaeoniflorin (200 μM; 0-14 d) inhibits TNF-α-induced proliferation of human HaCaT keratinocytes by arresting cell cycle progression, and a sustained antiproliferative effect is observable within 14 d^[1].
Benzoylpaeoniflorin (200 μM) inhibits TNF-α-induced activation of the NF-κB pathway in human HaCaT keratinocytes, reduces the nuclear translocation of p-p65, and decreases the secretion of downstream proinflammatory cytokines IL-1β, IL-6 and CXCL10^[1].
Benzoylpaeoniflorin (0-10 μM; 9-30 h) inhibits LPS (HY-D1056)-induced mRNA and protein expression of IL-6 and TNF-α in HUVECs and THP-1 macrophages in a time- and dose-dependent manner^[2].
Benzoylpaeoniflorin (0-50 μM; 48 h) exhibits no cytotoxicity towards human umbilical vein endothelial cells (HUVECs) and THP-1 macrophages^[2].
Benzoylpaeoniflorin (2-10 μM; 9-30 h) inhibits LPS-induced iNOS mRNA and protein expression in a time- and dose-dependent manner, as well as NO production in human umbilical vein endothelial cells (HUVECs) induced by LPS + IFN-γ^[2].
Benzoylpaeoniflorin (2-10 μM; 7 h) inhibits the phosphorylation of NF-κB (p65) and mitogen-activated protein kinases (MAPKs, including p38, JNK, ERK) induced by LPS in human umbilical vein endothelial cells (HUVECs) and THP-1 macrophages in a time- and dose-dependent manner^[2].
Benzoylpaeoniflorin (5-100 μM; 24 h) inhibits HDC activity in *Klebsiella pneumoniae* cultures, and incubation at 100 μM for 24 h reduces histamine production by up to 50%^[3].
Benzoylpaeoniflorin (25 h) potently inhibits IgE-mediated mast cell degranulation in DNP-BSA-stimulated RBL-2H3 cells: it exhibits an EC₅₀ of 6.34 μM for inhibiting β-HEX and an EC₅₀ of 18.06 μM for inhibiting HIS, and shows no cytotoxicity at concentrations up to 100 μM^[3].
Benzoylpaeoniflorin (5-100 μM; 25 h) downregulates the production of proinflammatory cytokines IL-3, IL-4, IL-5 and IL-13 in DNP-BSA-stimulated RBL-2H3 cells^[3].
Benzoylpaeoniflorin inhibits the activation of the MAPK signaling pathway in DNP-BSA-stimulated RBL-2H3 cells by reducing the phosphorylation levels of p38, ERK1/2 and JNK proteins^[3].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Cell Cytotoxicity Assay^[1]

Cell Line:	Human HaCaT keratinocytes
Concentration:	0, 50, 100, 200, 300, 400, 600, 800 μM
Incubation Time:	24, 48, 72 h
Result:	Showed no significant cytotoxicity at concentrations below 200 μM after 72 h of continuous treatment. Induced a dose-dependent and time-dependent decrease in cell viability at concentrations exceeding 300 μM. Reduced cell survival rate to less than 50% after 72 h exposure at concentrations above 400 μM.

ELISA Assay^[3]

Cell Line:	DNP-BSA-stimulated RBL-2H3 cells
Concentration:	5, 25, 100 μM
Incubation Time:	24 h (prior to 1 h DNP-BSA stimulation)
Result:	Markedly downregulated the overproduction of IL-3, IL-4, IL-5, and IL-13 compared to the model group.

In Vivo

Benzoylpaeoniflorin (0.3-0.6% cream; topical administration; once daily; for 7 consecutive days) significantly alleviates imiquimod (HY-B0180)-induced psoriasiform inflammation in female SKH-1 mice by restoring immune homeostasis, reducing keratinocyte proliferation, and inhibiting the TNF-α/NF-κB signaling pathway^[1].
Benzoylpaeoniflorin (0.09-0.44 mg/kg; intravenous injection; single administration concurrent with LPS treatment) dose-dependently reduces the production of inflammatory cytokines in serum and peritoneal fluid of LPS-induced mice, alleviates lung tissue injury in mice with non-lethal sepsis, and improves the survival rate of mice^[2].
Benzoylpaeoniflorin (45-180 mg/kg; p.o.; single administration) dose-dependently inhibits IgE-mediated passive cutaneous anaphylaxis in BALB/c mice^[3].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	SKH-1 hairless mice (female, 6 to 8-week-old)^[1]
Dosage:	0.3% cream; 0.6% cream
Administration:	topical; daily; 7 days
Result:	Improved the clinical symptoms and histological features of skin lesions. Regulated the proportion of immune cells, restores the balance of Th17/Treg cells, and alleviated inflammatory responses by inhibiting the TNF-α/NF-κB signaling pathway.

Animal Model:	C57BL/6 (male, 8-week-old, 27 ± 0.5 g, LPS-induced non-lethal septic shock model)^[2]
Dosage:	0.09, 0.22, 0.44 mg/kg
Administration:	i.v.; single dose concurrent with LPS administration
Result:	Reduced serum levels of IL-6, TNF-α, IL-1β, CXCL1, and CXCL2, as well as levels of these cytokines in peritoneal fluid. Significantly reduced histopathological scores of lung tissue (based on inflammatory cell infiltration and lesion area).\nAlleviated LPS-induced lung damage as shown by H&E staining. Achieved 40% survival rate (8 out of 20 mice) at 0.22 mg/kg. Achieved 60% survival rate (12 out of 20 mice) at 0.44 mg/kg. Control group had 10% survival rate (2 out of 20 mice).

Animal Model:	C57BL/6 (male, 8-week-old, 27 ± 0.5 g, cecal ligation and puncture (CLP)-induced sepsis model)^[2]
Dosage:	0.09, 0.22, 0.44 mg/kg
Administration:	i.v.; administered post-CLP; repeated every 24 hours (survival study)
Result:	Reduced levels of IL-6, TNF-α, and CXCL1 in peritoneal macrophages collected from CLP-operated mice. Achieved 45% survival rate (9 out of 20 mice) at 0.22 mg/kg for 96 hours. Achieved 65% survival rate (13 out of 20 mice) at 0.44 mg/kg for 96 hours.

Animal Model:	BALB/c (5-week-old male)^[3]
Dosage:	45 mg/kg; 90 mg/kg; 180 mg/kg
Administration:	p.o.; single dose
Result:	Reduced Evans blue dye leakage from mouse ears in a dose-dependent manner. Showed statistically significant decreases in absorbance at 620 nm compared to the model group for all tested doses.

Molecular Weight

584.57

Formula

C₃₀H₃₂O₁₂

CAS No.

38642-49-8

Appearance

Solid

Color

White to off-white

SMILES

O=C(C1=CC=CC=C1)OCC(C(C2(O)O3)C4)(C3OC5(C2)C)C45OC(C(C(O)C6O)O)OC6COC(C7=CC=CC=C7)=O

Structure Classification

Initial Source

Shipping

Room temperature in continental US; may vary elsewhere.

Storage

Powder	-20°C	3 years
	4°C	2 years
In solvent	-80°C	6 months
	-20°C	1 month

Solvent & Solubility

In Vitro:

DMSO : 100 mg/mL (171.07 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

Preparing
Stock Solutions

Concentration Solvent Mass	1 mg	5 mg	10 mg

1 mM	1.7107 mL	8.5533 mL	17.1066 mL
5 mM	0.3421 mL	1.7107 mL	3.4213 mL
10 mM	0.1711 mL	0.8553 mL	1.7107 mL

View the Complete Stock Solution Preparation Table

* Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

Molarity Calculator
Dilution Calculator

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Concentration _(start) × Volume _(start) = Concentration _(final) × Volume _(final)

This equation is commonly abbreviated as: C₁V₁ = C₂V₂

Concentration _(start)

Volume _(start)

Concentration _(final)

Volume _(final)

In Vivo:

Select the appropriate dissolution method based on your experimental animal and administration route.

For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for in vivo experiments, it is recommended to prepare freshly and use it on the same day.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

Protocol 1

Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline
Solubility: ≥ 2.5 mg/mL (4.28 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.
Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
Protocol 2

Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)
Solubility: ≥ 2.5 mg/mL (4.28 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.
Preparation of 20% SBE-β-CD in Saline (4°C, storage for one week): 2 g SBE-β-CD powder is dissolved in 10 mL Saline, completely dissolve until clear.
Protocol 3

Add each solvent one by one: 10% DMSO 90% Corn Oil
Solubility: ≥ 2.5 mg/mL (4.28 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown). If the continuous dosing period exceeds half a month, please choose this protocol carefully.
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL Corn oil, and mix evenly.

In Vivo Dissolution Calculator

Please enter the basic information of animal experiments:

Dosage

mg/kg

Animal weight
(per animal)

Dosing volume
(per animal)

μL

Number of animals

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Please enter your animal formula composition:

DMSO +

Tween-80 +

Saline

Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.

The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).

Calculation results:

Working solution concentration: mg/mL

Method for preparing stock solution: mg drug dissolved in μL DMSO (Stock solution concentration: mg/mL).

The concentration of the stock solution you require exceeds the measured solubility. The following solution is for reference only. If necessary, please contact MedChemExpress (MCE).

Method for preparing in vivo working solution for animal experiments: Take μL DMSO stock solution, add μL . μL , mix evenly, next add μL Tween 80, mix evenly, then add μL Saline.

If the continuous dosing period exceeds half a month, please choose this protocol carefully.

Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.

Purity & Documentation

Purity: 99.35%

Select Batch:

Data Sheet (290 KB) SDS (393 KB)

COA (260 KB) RP-HPLC (206 KB)

Handling Instructions (2659 KB)

References

[1]. Wei J, et al. Benzoylpaeoniflorin alleviates psoriasis-like inflammation by modulating immune balance and inhibiting NF-κB signaling pathway. Bioorg Chem. 2025;163:108711. [Content Brief]

[2]. Kim C, et al. Benzoylpaeoniflorin Activates Anti-Inflammatory Mechanisms to Mitigate Sepsis in Cell-Culture and Mouse Sepsis Models. Int J Mol Sci. 2022;23(21):13130. Published 2022 Oct 28. [Content Brief]

[3]. Zhong WC, et al. Anti-anaphylactic potential of benzoylpaeoniflorin through inhibiting HDC and MAPKs from Paeonia lactiflora. Chin J Nat Med. 2021;19(11):825-835. [Content Brief]

Complete Stock Solution Preparation Table

Optional Solvent	Concentration Solvent Mass	1 mg	5 mg	10 mg	25 mg

DMSO	1 mM	1.7107 mL	8.5533 mL	17.1066 mL	42.7665 mL
	5 mM	0.3421 mL	1.7107 mL	3.4213 mL	8.5533 mL
	10 mM	0.1711 mL	0.8553 mL	1.7107 mL	4.2766 mL
	15 mM	0.1140 mL	0.5702 mL	1.1404 mL	2.8511 mL
	20 mM	0.0855 mL	0.4277 mL	0.8553 mL	2.1383 mL
	25 mM	0.0684 mL	0.3421 mL	0.6843 mL	1.7107 mL
	30 mM	0.0570 mL	0.2851 mL	0.5702 mL	1.4255 mL
	40 mM	0.0428 mL	0.2138 mL	0.4277 mL	1.0692 mL
	50 mM	0.0342 mL	0.1711 mL	0.3421 mL	0.8553 mL
	60 mM	0.0285 mL	0.1426 mL	0.2851 mL	0.7128 mL
	80 mM	0.0214 mL	0.1069 mL	0.2138 mL	0.5346 mL
	100 mM	0.0171 mL	0.0855 mL	0.1711 mL	0.4277 mL